Yuankai Shi, PhD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Hospital Chinese Academy of Medical Science · Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yuankai Shi, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:08 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06792253 · Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med Inc · recruiting · Relapsed/Refractory Diffuse Large B-Cell Lymphoma · principal investigator
- Ph1NCT06164327 · Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med Inc · unknown · Relapsed/Refractory Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT06074107 · Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma SubjectsBeBetter Med Inc · completed · Relapsed or Refractory Diffuse Large B-cell Lymphoma · principal investigator
- Ph2NCT05900219 · Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyShanghai Kechow Pharma, Inc. · unknown · Non-small-cell Lung Cancer · principal investigator
- Ph4NCT05219162 · Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).AstraZeneca · completed · Advanced NSCLC · principal investigator
- Ph1/Ph2NCT04304040 · A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaBeijing InnoCare Pharma Tech Co., Ltd. · unknown · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory · principal investigator
- N/ANCT03412344 · Factors Influencing Cancer Patients Participation in Clinical Trials in China.Chinese Academy of Medical Sciences · unknown · Cancer · principal investigator
- Ph2NCT02323737 · Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung CancerChinese Academy of Medical Sciences · completed · Extensive-stage Small Cell Lung Cancer · principal investigator
- Ph3NCT01459887 · Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's LymphomaShanghai CP Guojian Pharmaceutical Co., Ltd. · completed · Diffuse Large B Cell Lymphoma · principal investigator
- Ph2NCT01439191 · Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast CancerShanghai CP Guojian Pharmaceutical Co., Ltd. · completed · Metastatic Breast Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.